anazao health semaglutide Medical Weight Loss anazaohealth semaglutide Your Guide to

10.1016/j.cell.2021.05.030 Cell

Its authors found that use of semaglutide reduced: deaths from causes related to cardiovascular disease by 17% hospitalizations for heart failure by 76% non-fatal myocardial infarction (heart attack) by 24% the need for coronary revascularization by 24% strokes in people with diabetes by 35% deaths from any cause by 21%

(, , ), ,

All are compounded formulations - not FDA-approved branded products

While more research is needed to fully understand the relationship between PFAS exposure and pancreatic cancer, initial findings point to a troubling correlation

This is a normal physiological response to caloric deficit and increased fat metabolism